(Vax-Before-Travel News)
While the European CDC says Chikungunya is not endemic in mainland EU/EEA, outbreaks have been reported in 2025.
According to the latest ECDC Communicable Disease Threats Report, as of August 6, 2025, France and Italy have reported locally acquired cases of chikungunya virus disease:
France’s health authorities have identified 63 locally acquired cases of Chikungunya across 16 different local administrative units.
Currently, there are eleven active clusters. Notably, cases were reported for the first time in the Pyrénées-Atlantiques department, with three instances in one cluster. Additionally, three cases representing a new cluster were reported in Gard.
In the active clusters located in the departments of Corse-du-Sud, Isère, Hérault, and Bouches-du-Rhône, two new cases have been reported in each cluster.
The most significant clusters are in southern France, specifically in Salon-de-Provence, Grans, and Lambesc in the Bouches-du-Rhône department, as well as Grosseto-Prugna in the Corse-du-Sud department, with each cluster consisting of 13 cases.
In Italy, two clusters remain active.
For the current risk assessment of chikungunya virus disease in mainland EU/EEA, please visit the ECDC’s dedicated chikungunya webpage.
Fortunately, chikungunya vaccines are approved for use in Europe and the United States.
The U.S. CDC advises international travelers to speak with a travel vaccine expert regarding immunization options. Chikungunya vaccines are commercailly offered at select retailers.